These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38842323)

  • 1. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
    Motta I; Cusinato M; Ludman AJ; Lachenal N; Dodd M; Soe M; Abdrasuliev T; Usmanova R; Butabekov I; Nikolaevna TZ; Liverko I; Parpieva N; Moodliar R; Solodovnikova V; Kazounis E; Nyang'wa B-T; Fielding KL; Berry C
    Antimicrob Agents Chemother; 2024 Jul; 68(7):e0053624. PubMed ID: 38842323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
    Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Moodliar R; Dodd M; Solodovnikova V; Liverko I; Rajaram S; Rassool M; McHugh T; Spigelman M; Moore DA; Ritmeijer K; du Cros P; Fielding K;
    Lancet Respir Med; 2024 Feb; 12(2):117-128. PubMed ID: 37980911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clofazimine and QT prolongation in the treatment of rifampicin-resistant tuberculosis: Findings of aDSM in Taiwan.
    Lin CJ; Chen JH; Chien ST; Huang YW; Lin CB; Lee JJ; Lee CH; Yu MC; Chiang CY
    J Microbiol Immunol Infect; 2024 Oct; 57(5):791-800. PubMed ID: 39160114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
    Berry C; du Cros P; Fielding K; Gajewski S; Kazounis E; McHugh TD; Merle C; Motta I; Moore DAJ; Nyang'wa BT
    Trials; 2022 Jun; 23(1):484. PubMed ID: 35698158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
    Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
    James LP; Klaassen F; Sweeney S; Furin J; Franke MF; Yaesoubi R; Chesov D; Ciobanu N; Codreanu A; Crudu V; Cohen T; Menzies NA
    PLoS Med; 2024 May; 21(5):e1004401. PubMed ID: 38701084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
    Li H; Salinger DH; Everitt D; Li M; Del Parigi A; Mendel C; Nedelman JR
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
    Günther G; Guglielmetti L; Kherabi Y; Duarte R; Lange C;
    Clin Microbiol Infect; 2024 Sep; 30(9):1197.e1-1197.e4. PubMed ID: 38490355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.
    Ali AM; Radtke KK; Hesseling AC; Winckler J; Schaaf HS; Draper HR; Solans BP; van der Laan L; Hughes J; Fourie B; Nielsen J; Garcia-Prats AJ; Savic RM
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0144822. PubMed ID: 37358463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Cevik M; Thompson LC; Upton C; Rolla VC; Malahleha M; Mmbaga B; Ngubane N; Abu Bakar Z; Rassool M; Variava E; Dawson R; Staples S; Lalloo U; Louw C; Conradie F; Eristavi M; Samoilova A; Skornyakov SN; Ntinginya NE; Haraka F; Praygod G; Mayanja-Kizza H; Caoili J; Balanag V; Dalcolmo MP; McHugh T; Hunt R; Solanki P; Bateson A; Crook AM; Fabiane S; Timm J; Sun E; Spigelman M; Sloan DJ; Gillespie SH;
    Lancet Infect Dis; 2024 Sep; 24(9):1003-1014. PubMed ID: 38768617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study.
    Li R; Ma JB; Yang H; Yang H; Yang XJ; Wu YQ; Ren F
    Microbiol Spectr; 2023 Aug; 11(4):e0104823. PubMed ID: 37310268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QT prolongation in the STREAM Stage 1 Trial.
    Hughes G; Bern H; Chiang CY; Goodall RL; Nunn AJ; Rusen ID; Meredith SK
    Int J Tuberc Lung Dis; 2022 Apr; 26(4):334-340. PubMed ID: 35351238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.
    Liu F; Gao J; Gao M; Liu Y; Shu W; Xie L; Sun Y; Zhang L; Li L; Pang Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0203321. PubMed ID: 36047781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China.
    Song Y; Shu W; Pei Y; Du J; Wu G; Wang H; Mi F; Liu F; Ma L; Xie L; Kong Z; Wu X; Liu R; Chen H; Li H; Ge Q; Nie L; Lv Z; Huang X; Li M; Jiang M; Chen X; Cai Q; Chen W; Liu Y; Miao Y; Tang Y; Chen Y; Geng S; Zhou Q; Liu Y; Pang Y; Gao M
    BMC Med; 2024 Sep; 22(1):401. PubMed ID: 39300460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
    Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Solodovnikova V; Liverko I; Moodliar R; Dodd M; Ngubane N; Rassool M; McHugh TD; Spigelman M; Moore DAJ; Ritmeijer K; du Cros P; Fielding K;
    N Engl J Med; 2022 Dec; 387(25):2331-2343. PubMed ID: 36546625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study.
    Brust JCM; Gandhi NR; Wasserman S; Maartens G; Omar SV; Ismail NA; Campbell A; Joseph L; Hahn A; Allana S; Hernandez-Romieu AC; Zhang C; Mlisana K; Viljoen CA; Zalta B; Ebrahim I; Franczek M; Master I; Ramangoaela L; Te Riele J; Meintjes G
    Clin Infect Dis; 2021 Dec; 73(11):2083-2092. PubMed ID: 33882121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-wave morphology abnormalities in the STREAM stage 1 trial.
    Hughes G; Young WJ; Bern H; Crook A; Lambiase PD; Goodall RL; Nunn AJ; Meredith SK
    Expert Opin Drug Saf; 2024 Apr; 23(4):469-476. PubMed ID: 38462751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ECG monitoring in STREAM Stage 1: can we identify those at increased risk of QT prolongation?
    Hughes G; Bern H; Chiang CY; Goodall RL; Nunn AJ; Rusen ID; Meredith SK
    Int J Tuberc Lung Dis; 2022 Nov; 26(11):1065-1070. PubMed ID: 36281045
    [No Abstract]   [Full Text] [Related]  

  • 19. Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis.
    Evans D; Hirasen K; Ramushu C; Long L; Sinanovic E; Conradie F; Howell P; Padanilam X; Ferreira H; Variaiva E; Rajaram S; Gupta A; Juneja S; Ndjeka N
    PLoS One; 2024; 19(10):e0309034. PubMed ID: 39432463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
    Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
    Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.